NOVAREX Co.Ltd (194700) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of NOVAREX Co.Ltd stock KRW 25,770, price KRW 8,590, upside +200.0%, quality 64 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 6,414 KRW – 22,571 KRW · fair‑value band 12,168 KRW – 34,854 KRW · the 8,590 KRW price screens below the 25,770 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow NOVAREX Co.Ltd in your weekly email
Every Wednesday you see whether NOVAREX Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NOVAREX Co.,Ltd. manufactures, wholesales, and retails health and functional foods in South Korea and internationally.
Show moreShow less
It offers lactic acid bacteria, omega-3, icle time, eye health, diet, boswellia, and lutein and zeaxanthin, as well as vitamin and mineral products in the form of tablets, soft and hard capsules, powder, liquid, gel, and jellies.
The company was formerly known as Health Science Co., Ltd. and changed its name to NOVAREX Co.,Ltd. in November 2013. NOVAREX Co.,Ltd. was founded in 1995 and is headquartered in Cheongju-si, South Korea.
Stock analysis
NOVAREX Co.Ltd (194700) currently trades at 8,590 KRW, while our model-based Fair Value estimate is 25,770 KRW, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 55,937 KRW per share, and 23 of the 26 models we run sit above the 8,590 KRW price.
Bear case: the Asset-Based group reads lowest at 6,001 KRW, and 3 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 12,168 KRW (bear) to 34,854 KRW (bull), the price of 8,590 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
NOVAREX Co.Ltd reported revenue of 404B KRW in FY2025 versus 279B KRW in FY2021, a compound +9.7%/yr. Reported net income was 35.4B KRW in FY2025, compounding +7.6%/yr from FY2021.
Key figures
Market cap 152B KRW (≈ $112M) Micro · P/E ratio 4.3 · P/S ratio 0.38 · EPS (TTM) 1,995 KRW · Dividend yield 4.7% · Net margin 8.8% · Return on equity 15.2% · Return on assets (EBIT) 10.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −1% fair-value upside, at 200%, 194700 screens cheaper than that median.
Fair Value models
Bear12,168 KRWFair Value 25,770 KRWBull34,854 KRW
Price 8,590 KRW · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1,368 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+35.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Start year 2020 (pandemic). Over 10 years: +17.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+9.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.0%
Dividend (yield on the price)4.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5.2% vs 13.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 11%
2025 sits 61% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +17.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 625 stocks
Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Top 25%
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)15.2% · Top 25%
Return on assets9.9% · Top 25%
Net margin (12 months)8.8% · Top 25%
Operating margin (12 months)10.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)22.5% · Top 25%
Dividend yield (12 months)4.7% · Top 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
P/E (12 months)4.3× · Cheapest 25%
P/B0.60× · Cheapest 25%
P/S (12 months)0.38× · Cheaper than median
Price / free cash flow (fiscal year)24.6× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "NOVAREX Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/194700
Frequently asked questions
Is NOVAREX Co.Ltd (194700) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 25,770 KRW versus a price of 8,590 KRW, about +200% upside (undervalued).
What is the fair value of 194700?
Our model-based fair value for NOVAREX Co.Ltd is 25,770 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 8,590 KRW.
What is the quality score of 194700?
NOVAREX Co.Ltd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NOVAREX Co.Ltd (194700)?
Our model-based price target is the fair value of 25,770 KRW (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 12,168 KRW, optimistic scenario 34,854 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the NOVAREX Co.Ltd stock forecast for 2026?
Our models put fair value at 25,770 KRW, about +200% upside versus a price of 8,590 KRW (undervalued). Cautious scenario 12,168 KRW, optimistic scenario 34,854 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of NOVAREX Co.Ltd (194700)?
NOVAREX Co.Ltd reported trailing-twelve-month revenue of about 404B KRW (latest available figure, as of Nov 8, 2026).
Does NOVAREX Co.Ltd pay a dividend?
NOVAREX Co.Ltd currently shows a dividend yield of 4.66% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of NOVAREX Co.Ltd (194700) and when is the ex-dividend date?
NOVAREX Co.Ltd pays a dividend of 400.00 KRW per share a year, a dividend yield of 4.7%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2018. The payout ratio is 20.1% of earnings. Free cash flow covers the dividend 0.87 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into NOVAREX Co.Ltd (194700)?
For today's price to be fair in a discounted-cash-flow model, NOVAREX Co.Ltd would have to grow free cash flow by +20.0 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.7 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 194700 use?
Our models discount NOVAREX Co.Ltd at 11.6 %: a base by market capitalisation (micro), damped by beta 0.29, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For NOVAREX Co.Ltd that is +20.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has NOVAREX Co.Ltd (194700) delivered so far?
Over the past 5 years revenue at NOVAREX Co.Ltd grew +12.7 % a year. The price currently implies free-cash-flow growth of +20.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of NOVAREX Co.Ltd (194700) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into NOVAREX Co.Ltd (+20.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of NOVAREX Co.Ltd (194700)?
The free-cash-flow yield on the price is 4.06 %: that much free cash flow NOVAREX Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of NOVAREX Co.Ltd (194700)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NOVAREX Co.Ltd it is 25,770 KRW per share (as of Nov 8, 2026), against a price of 8,590 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is NOVAREX Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 194700 trades below its calculated fair value: price 8,590 KRW, fair value 25,770 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 194700?
No. The price is what the market pays today (8,590 KRW); the fair value is what the company's own numbers justify (25,770 KRW). For NOVAREX Co.Ltd the two are 17,180 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is NOVAREX Co.Ltd worth?
The market values NOVAREX Co.Ltd at about 152B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 8,590 KRW; our models calculate a fair value of 25,770 KRW per share.
What do the bullish and bearish scenarios say about 194700?
Our models span a range for NOVAREX Co.Ltd: cautious scenario 12,168 KRW, base 25,770 KRW, optimistic 34,854 KRW per share (as of Nov 8, 2026, price 8,590 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 194700?
NOVAREX Co.Ltd trades at a price-to-earnings ratio of 4.3 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 25,770 KRW is built from several models across several years. Other multiples: P/B 0.6, P/S 0.4, EV/EBITDA 2.1.
How solid is the balance sheet of NOVAREX Co.Ltd (194700)?
Balance-sheet figures for NOVAREX Co.Ltd (as of Nov 8, 2026): return on equity 15.2%, debt of 0.03 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 194700 from its 52-week high?
NOVAREX Co.Ltd trades at 8,590 KRW, about 53% below its 52-week high of 18,220 KRW and at the low of 8,590 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 25,770 KRW is for.
Which stocks are comparable to NOVAREX Co.Ltd?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NOVAREX Co.Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 8,590 KRW, calculated fair value 25,770 KRW (+200%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 194700 calculated?
We run NOVAREX Co.Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 25,770 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. NOVAREX Co.Ltd currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NOVAREX Co.Ltd (194700)?
The closing price on Nov 6, 2026 was 8,590 KRW. Our model-based fair value is 25,770 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NOVAREX Co.Ltd right now?
The price is below even our cautious bear case (12,168 KRW). The market is more pessimistic than our downside scenario. The model range is unusually wide (12,168 KRW to 34,854 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of NOVAREX Co.Ltd
How large is the market capitalisation of NOVAREX Co.Ltd (194700)?
The market capitalisation of NOVAREX Co.Ltd is 152B KRW (≈ $112M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NOVAREX Co.Ltd (194700)?
The price-to-sales ratio of NOVAREX Co.Ltd is 0.38 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NOVAREX Co.Ltd (194700)?
Earnings per share at NOVAREX Co.Ltd are 1,995 KRW (price ÷ EPS = P/E 4.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of NOVAREX Co.Ltd (194700)?
The dividend yield of NOVAREX Co.Ltd is 4.7% (payout 20.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of NOVAREX Co.Ltd (194700)?
The net margin of NOVAREX Co.Ltd is 8.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NOVAREX Co.Ltd (194700)?
The return on equity (ROE) of NOVAREX Co.Ltd is 15.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NOVAREX Co.Ltd (194700)?
On an EBIT basis the return on assets of NOVAREX Co.Ltd is 10.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NOVAREX Co.Ltd (194700)?
The operating margin of NOVAREX Co.Ltd is 10.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NOVAREX Co.Ltd (194700)?
Revenue at NOVAREX Co.Ltd is growing +22.5% versus a year earlier (3y avg +12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at NOVAREX Co.Ltd (194700)?
Earnings per share at NOVAREX Co.Ltd are growing −7.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does NOVAREX Co.Ltd (194700) carry?
The net debt of NOVAREX Co.Ltd is 18.3B KRW (fiscal year 2022, ≈ 3.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch NOVAREX Co.Ltd in the live analysis
One click puts NOVAREX Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026